Akebia Therapeutics Revenue, Profits - AKBA Annual Income Statement

Add to My Stocks
$8.28 $0.05 (0.6%) AKBA stock closing price Sep 21, 2018 (Closing)

Looking at financial statements, along with the Akebia Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $177.98M for 2017 impacts the AKBA stock. Investors typically check year over year or quarter over quarter revenue growth. One also needs to look at Akebia Therapeutics assets, operating expenses and Akebia Therapeutics free cash flow. The Akebia Therapeutics profit and loss statement shows revenue of $177.98M for 2017. Revenue has grown by 11532.68% YOY for AKBA stock.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012
Akebia Therapeutics Revenues or Net Sales
177.98M1.53M----
Cost Of Goods Sold (COGS)------
Akebia Therapeutics Gross Profit
177.98M1.53M----
Research & Development Expense230.89M115.78M43.01M25.39M10.78M5.63M
Selling General & Admin Expense27M22.21M18.49M12.54M5.15M2.89M
Income Before Depreciation Depletion Amortization-79.91M-136.46M-61.51M-37.94M-15.93M-8.52M
Depreciation Depletion Amortization------
Non Operating Income3M---3.46M1.97M
Interest Expense-----1.64M
Akebia Therapeutics Pretax Income
-76.91M-135.74M-60.71M-37.03M-13.16M-8.19M
Provision for Income Taxes------
MinorityInterest------
Investment Gains Losses------
Other Income------
Income Before Extraordinaries & Disc Operations-76.91M-135.74M-60.71M-37.03M-13.16M-8.19M
Extraordinary Items & Discontinued Operations------
Akebia Therapeutics Profit/ Loss (Net Income)
-76.91M-135.74M-60.71M-37.03M-13.16M-8.19M
Average Shares used to compute Diluted EPS43.5M37.72M26.47M15.41M10.13M-
Average Shares used to compute Basic EPS43.5M37.72M26.47M15.41M10.13M-
Income Before Nonrecurring Items-76.91M-135.75M-60.72M-37.03M-13.17M-
Income from Nonrecurring Items------
Akebia Therapeutics Earnings Per Share Basic Net
-1.77-3.60-2.29-8.04-1.31-
Akebia Therapeutics Earnings Per Share Diluted Net
-1.77-3.60-2.29-8.04-1.31-
EPS Diluted Before Nonrecurring Items-1.77-3.60-2.29-8.04-1.31-
Preferred Dividends Acc Pd------
Dividends Common------
Dividend Per Share Common0.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The key things to look for in an income statement while doing Akebia Therapeutics stock analysis are:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $177.98M for this year of 2017. Our Akebia Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-76.91M for AKBA stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The AKBA financials along with Akebia Therapeutics historical stock prices provide a lot of details about the firm.

Akebia Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
2.11
Dividend Yield
0%